rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2000-150rsp-485Research ArticleСтатьиArticlesМЕЛОКСИКАМ (МОВАЛИС) - СЕЛЕКТИВНЫЙ ИНГИБИТОР ЦОГ-2 В КЛИНИЧЕСКОЙ ПРАКТИКЕMELOXICAM (MOVAL1S): THE SELECTIVE INHIBITOR OF COX-2 IN CLINICAL PRACTICENassonovaV ANassonovaV A
дир. - академик РАМН - В.А.Насонова
dir. - akademik RAMN - V.A.Nasonova
-200015082000384№4 (2000)22Copyright © Nassonova V.A., 20002000Nassonova V.A.Nassonova V.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/485References<div><p>Коган К.М., Золотарева Г.Д., Шмидт Е.И. Опыт применения мовалиса у больных остеоартрозом в клиниках Москвы. Тер. Архив, 1999, 11, 52-54.</p><p>Насонов Е.Л., Цветкова Е.С., Балабанова P.M. с соавт. Новые аспекты противовоспалительной терапии ревматических болезней: теоретические предпосылки и клиническое применение мелоксикама. Клин. Медицина, 1996, 4, 4-8.</p><p>Насонова В.А. Новые данные о клинической эффективности и переносимости мелоксикама (мовалиса). Тер. Архив, 1999, 11, 4548.</p><p>Цветкова Е.С. Мовалис при остеоартрозе. Тер. Архив, 1999, 11, 48-50.</p><p>Шостак Н.А. Опыт применения мовалиса при синдроме болей в нижней части спины (LBP). Тер. Архив, 1999, 11, 50-52.</p><p>Boulton -Jones J.M., Geddes C.G., Heinzel G. et al. Meloxicam pharmacokinetics in renal impairment Br. J. Clin. Pharmacol, 1997, 43, 35-40.</p><p>Busch U., Heinzel G., Narjes H. et al. Pharmacokinetics of Meloxicam in patients with hepatic cirrhosis in comparison with healthy volunteers. Clin. Drug Invest, 1996, 11, 97107.</p><p>Chesne C., Guyomard C., Guillozo S. et al. Metabolism of Meloxicam by Human liver involves Cytochromes 2C9 and 3A4. Exp. Toxical. Phatol, 1996, 48,.406-410.</p><p>Degner F., Turk D., Pairet M. Meloxicam. Pharmacological, Pharmacokinetic and Clinical Profil. Drugs of Today, 1998, 34, Suppl A, 1-22.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cycloxyganase (COX-2) inhibition Meloxicam, compared with piroxicam: result of the safety and efficacy Large-Scale evaluation of COX - inhibiting therapies (SELECT) trial in osteoarthritis. Brit. J. Rheumatol., 1998, 37, 9, 946-995.</p><p>Distel М., Mueller C., Bluhmki E., Fries J. Safely of meloxicam: a global analysis of clinical trial Br. J. Rheumatol., 1996, 35, Suppl 1, 68-71.</p><p>Hawkey C., Kahan A, Steinbruk K. et al. Gastrointestinal tolerability of Meloxicam compared to diclofenac in osteoarthritis patients. Brit. J. Rheumatol., 1998,37,9, 937-945.</p><p>Lapicque F., Gillet P., Vignon et, al. Diffuss- ion of Meloxicam into Synovial fluid after a single oral dose. Rheumatol. Eur., 1996, 25, Suppl. 1, 444-446.</p><p>Mohr W., Lehmann H., Engelhardt G., Chon- droneutrality of meloxicam in rats with spontaneous osteoarthritis of the ankle joints J. Rheumatol., 1997, 56, 21-30.</p><p>Rainsford, К D Skerry T.M., Chindemi P., Delaney K. Effects of the NSAIDs Meloxicam and Indomethacin on cartilage Proteoglycan Synthesis and Joint Responses to calcium Pyrophosphate Crystals in Dogs. Veterinary Reserch. Commun., 1999, 23, 101-113.</p><p>Shoenfeld Ph. Gastrointestinal Safety Profile of Meloxicam: A Meta- analysis and Systemic Review of Randomized Controlled Trials. Amer. J.Med., 1999, 107, 19, 48-54.</p><p>Zeidler H. Meloxicam in einer doppelblinden klinischen prufung bei spondyloitois anky- losant sowil in rahmen einer afifenen epidemi- ologischen beobachtungsstudie COX-2 Hem- mung: Von der Wissenschaft zur Klinik Satel- liten. Symposium Baden-Baden, 1998, 24-26.</p></div><br /><div><p>Коган К.М., Золотарева Г.Д., Шмидт Е.И. Опыт применения мовалиса у больных остеоартрозом в клиниках Москвы. Тер. Архив, 1999, 11, 52-54.</p><p>Насонов Е.Л., Цветкова Е.С., Балабанова P.M. с соавт. Новые аспекты противовоспалительной терапии ревматических болезней: теоретические предпосылки и клиническое применение мелоксикама. Клин. Медицина, 1996, 4, 4-8.</p><p>Насонова В.А. Новые данные о клинической эффективности и переносимости мелоксикама (мовалиса). Тер. Архив, 1999, 11, 4548.</p><p>Цветкова Е.С. Мовалис при остеоартрозе. Тер. Архив, 1999, 11, 48-50.</p><p>Шостак Н.А. Опыт применения мовалиса при синдроме болей в нижней части спины (LBP). Тер. Архив, 1999, 11, 50-52.</p><p>Boulton -Jones J.M., Geddes C.G., Heinzel G. et al. Meloxicam pharmacokinetics in renal impairment Br. J. Clin. Pharmacol, 1997, 43, 35-40.</p><p>Busch U., Heinzel G., Narjes H. et al. Pharmacokinetics of Meloxicam in patients with hepatic cirrhosis in comparison with healthy volunteers. Clin. Drug Invest, 1996, 11, 97107.</p><p>Chesne C., Guyomard C., Guillozo S. et al. Metabolism of Meloxicam by Human liver involves Cytochromes 2C9 and 3A4. Exp. Toxical. Phatol, 1996, 48,.406-410.</p><p>Degner F., Turk D., Pairet M. Meloxicam. Pharmacological, Pharmacokinetic and Clinical Profil. Drugs of Today, 1998, 34, Suppl A, 1-22.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cycloxyganase (COX-2) inhibition Meloxicam, compared with piroxicam: result of the safety and efficacy Large-Scale evaluation of COX - inhibiting therapies (SELECT) trial in osteoarthritis. Brit. J. Rheumatol., 1998, 37, 9, 946-995.</p><p>Distel М., Mueller C., Bluhmki E., Fries J. Safely of meloxicam: a global analysis of clinical trial Br. J. Rheumatol., 1996, 35, Suppl 1, 68-71.</p><p>Hawkey C., Kahan A, Steinbruk K. et al. Gastrointestinal tolerability of Meloxicam compared to diclofenac in osteoarthritis patients. Brit. J. Rheumatol., 1998,37,9, 937-945.</p><p>Lapicque F., Gillet P., Vignon et, al. Diffuss- ion of Meloxicam into Synovial fluid after a single oral dose. Rheumatol. Eur., 1996, 25, Suppl. 1, 444-446.</p><p>Mohr W., Lehmann H., Engelhardt G., Chon- droneutrality of meloxicam in rats with spontaneous osteoarthritis of the ankle joints J. Rheumatol., 1997, 56, 21-30.</p><p>Rainsford, К D Skerry T.M., Chindemi P., Delaney K. Effects of the NSAIDs Meloxicam and Indomethacin on cartilage Proteoglycan Synthesis and Joint Responses to calcium Pyrophosphate Crystals in Dogs. Veterinary Reserch. Commun., 1999, 23, 101-113.</p><p>Shoenfeld Ph. Gastrointestinal Safety Profile of Meloxicam: A Meta- analysis and Systemic Review of Randomized Controlled Trials. Amer. J.Med., 1999, 107, 19, 48-54.</p><p>Zeidler H. Meloxicam in einer doppelblinden klinischen prufung bei spondyloitois anky- losant sowil in rahmen einer afifenen epidemi- ologischen beobachtungsstudie COX-2 Hem- mung: Von der Wissenschaft zur Klinik Satel- liten. Symposium Baden-Baden, 1998, 24-26.</p></div><br />
The authors declare that there are no conflicts of interest present.